- Home
- PLBY vs YARW Comparison
PLBY vs YARW Comparison
Compare PLBY & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLBY | YARW |
|---|---|---|
| Founded | 1953 | N/A |
| Country | United States | United States |
| Employees | 588 | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.4M | 114.6M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PLBY | YARW |
|---|---|---|
| Price | $1.04 | $25.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 476.4K | 120.7K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $120,928,000.00 | N/A |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.13 | N/A |
| 52 Week Low | $1.03 | $24.00 |
| 52 Week High | $2.75 | $44.28 |
Technical Indicators
Market Signals| Indicator | PLBY | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 31.20 | 36.07 |
| Support Level | N/A | $24.00 |
| Resistance Level | $1.30 | $32.89 |
| Average True Range (ATR) | 0.04 | 2.86 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 16.65 |
Price Performance
Historical ComparisonAbout PLBY PLBY Group Inc.
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.